These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30150994)

  • 21. Immunomodulation of curcumin on adoptive therapy with T cell functional imaging in mice.
    Chang YF; Chuang HY; Hsu CH; Liu RS; Gambhir SS; Hwang JJ
    Cancer Prev Res (Phila); 2012 Mar; 5(3):444-52. PubMed ID: 22135043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells.
    Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
    Immunology; 2015 Oct; 146(2):292-300. PubMed ID: 26147366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor.
    Moyer BJ; Rojas IY; Murray IA; Lee S; Hazlett HF; Perdew GH; Tomlinson CR
    Toxicol Appl Pharmacol; 2017 May; 323():74-80. PubMed ID: 28336214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase.
    Reddy SV; Reddy KT; Kumari VV; Basha SH
    J Biomol Struct Dyn; 2015; 33(12):2695-709. PubMed ID: 25671592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferase I activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells.
    Eleftheriadis T; Pissas G; Sounidaki M; Tsogka K; Antoniadis N; Antoniadi G; Liakopoulos V; Stefanidis I
    Int J Mol Med; 2016 Nov; 38(5):1605-1613. PubMed ID: 27667153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond.
    Orabona C; Grohmann U
    Methods Mol Biol; 2011; 677():269-80. PubMed ID: 20941617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy.
    Lin SY; Yeh TK; Kuo CC; Song JS; Cheng MF; Liao FY; Chao MW; Huang HL; Chen YL; Yang CY; Wu MH; Hsieh CL; Hsiao W; Peng YH; Wu JS; Lin LM; Sun M; Chao YS; Shih C; Wu SY; Pan SL; Hung MS; Ueng SH
    J Med Chem; 2016 Jan; 59(1):419-30. PubMed ID: 26653033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression.
    Lu J; Liu X; Liao YP; Salazar F; Sun B; Jiang W; Chang CH; Jiang J; Wang X; Wu AM; Meng H; Nel AE
    Nat Commun; 2017 Nov; 8(1):1811. PubMed ID: 29180759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
    Zhu MMT; Dancsok AR; Nielsen TO
    Curr Oncol Rep; 2019 Jan; 21(1):2. PubMed ID: 30659394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDO decreases glycolysis and glutaminolysis by activating GCN2K, while it increases fatty acid oxidation by activating AhR, thus preserving CD4+ T‑cell survival and proliferation.
    Eleftheriadis T; Pissas G; Liakopoulos V; Stefanidis I
    Int J Mol Med; 2018 Jul; 42(1):557-568. PubMed ID: 29693118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comment on "Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression".
    Sørensen RB; thor Straten P; Andersen MH
    J Immunol; 2009 Nov; 183(10):6040. PubMed ID: 19890063
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.
    Muller AJ; Scherle PA
    Nat Rev Cancer; 2006 Aug; 6(8):613-25. PubMed ID: 16862192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
    Munn DH
    Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Marine natural products and other derivatives as potent indoleamine 2,3-dioxygenase inhibitors.
    Delfourne E
    Mini Rev Med Chem; 2012 Sep; 12(10):988-96. PubMed ID: 22512584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.
    Di Pucchio T; Danese S; De Cristofaro R; Rutella S
    Expert Opin Ther Pat; 2010 Feb; 20(2):229-50. PubMed ID: 20100004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbiota control of a tryptophan-AhR pathway in disease tolerance to fungi.
    Romani L; Zelante T; De Luca A; Iannitti RG; Moretti S; Bartoli A; Aversa F; Puccetti P
    Eur J Immunol; 2014 Nov; 44(11):3192-200. PubMed ID: 25256754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tryptophan catabolism and T cell responses.
    Mellor AL; Munn D; Chandler P; Keskin D; Johnson T; Marshall B; Jhaver K; Baban B
    Adv Exp Med Biol; 2003; 527():27-35. PubMed ID: 15206713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The benefits of immunotherapy combinations.
    Schmidt C
    Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of Indoleamine 2,3 Dioxygenase Inhibitor on the Cytotoxic Activity of Tumour-infiltrating Lymphocytes.
    Le Naour S; Knol AC; Pandolfino MC; Khammari A; Dréno B
    Acta Derm Venereol; 2019 Nov; 99(12):1186-1187. PubMed ID: 31408178
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of indoleamine 2,3-dioxygenase in mixed lymphocyte reaction affects glucose influx and enzymes involved in aerobic glycolysis and glutaminolysis in alloreactive T-cells.
    Eleftheriadis T; Pissas G; Yiannaki E; Markala D; Arampatzis S; Antoniadi G; Liakopoulos V; Stefanidis I
    Hum Immunol; 2013 Dec; 74(12):1501-9. PubMed ID: 23993986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.